Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Acute bronchitis in adults

INTRODUCTION

Acute bronchitis is one of the most common conditions encountered in clinical practice. It is a self-limited inflammation of the bronchi due to upper airway infection. Patients with acute bronchitis present with a cough lasting more than five days (typically one to three weeks), which may be associated with sputum production. Acute bronchitis should be distinguished from chronic bronchitis, a condition in patients with chronic obstructive pulmonary disease distinguished by a cough for at least three months in each of two successive years. (See "Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging", section on 'Definitions'.)

This respiratory condition is generally caused by a virus. However, reports indicate that more than 60 to 90 percent of patients with acute bronchitis who seek care are given antibiotics [1-4]. Additionally, 75 percent of all antibiotic prescriptions are written for upper respiratory infections [5].

Guidelines from the American College of Physicians [6] and the Centers for Disease Control and Prevention (CDC) [7] are intended to dissuade clinicians from prescribing antibiotics for acute bronchitis [7]. Both guidelines state unequivocally that pertussis is the only indication for antibacterial agents in the treatment of acute bronchitis. However, the frequency of prescriptions for antibiotics for acute bronchitis has decreased only modestly, from approximately 75 to 60 percent in over 10 years from guideline distribution [8]. Additionally, the choice of antibiotics prescribed for the treatment of acute bronchitis has changed substantially during the same time span. Prior to 1990, approximately 20 percent of antibiotics prescribed for the treatment of acute bronchitis were broad spectrum; more recently, approximately 60 percent of all prescriptions written for this condition were for broad-spectrum agents [8,9].

Acute bronchitis caused by microbial infection will be reviewed here. Exacerbations of chronic bronchitis and treatment of viral upper respiratory infections are discussed separately. (See "Management of infection in exacerbations of chronic obstructive pulmonary disease" and "The common cold in adults: Treatment and prevention".)

MICROBIOLOGY

The usual causes of acute bronchitis are viral infections of the upper airways including influenza A and B, parainfluenza, coronavirus (types 1-3), rhinovirus, respiratory syncytial virus, and human metapneumovirus [10]. Several case series examined the etiology of acute bronchitis in patients without underlying lung disease [11,12]. An etiologic agent was established in a minority of cases (29 percent of 42 episodes in one study [12], 16 percent of 113 patients in another [13]); viruses were the most common agents identified in both studies.

                        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: May 27, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997; 278:901.
  2. Gonzales R, Steiner JF, Lum A, Barrett PH Jr. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA 1999; 281:1512.
  3. Evertsen J, Baumgardner DJ, Regnery A, Banerjee I. Diagnosis and management of pneumonia and bronchitis in outpatient primary care practices. Prim Care Respir J 2010; 19:237.
  4. Kroening-Roche JC, Soroudi A, Castillo EM, Vilke GM. Antibiotic and bronchodilator prescribing for acute bronchitis in the emergency department. J Emerg Med 2012; 43:221.
  5. Schuetz P, Amin DN, Greenwald JL. Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 2012; 141:1063.
  6. Snow V, Mottur-Pilson C, Gonzales R, et al. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med 2001; 134:518.
  7. Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Intern Med 2001; 134:521.
  8. Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann Intern Med 2003; 138:525.
  9. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 2003; 9:432.
  10. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003; 187:785.
  11. Boldy DA, Skidmore SJ, Ayres JG. Acute bronchitis in the community: clinical features, infective factors, changes in pulmonary function and bronchial reactivity to histamine. Respir Med 1990; 84:377.
  12. Jonsson JS, Sigurdsson JA, Kristinsson KG, et al. Acute bronchitis in adults. How close do we come to its aetiology in general practice? Scand J Prim Health Care 1997; 15:156.
  13. MacKay DN. Treatment of acute bronchitis in adults without underlying lung disease. J Gen Intern Med 1996; 11:557.
  14. Denny FW, Clyde WA Jr, Glezen WP. Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control. J Infect Dis 1971; 123:74.
  15. Wadowsky RM, Castilla EA, Laus S, et al. Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as etiologic agents of persistent cough in adolescents and adults. J Clin Microbiol 2002; 40:637.
  16. Foy HM, Kenny GE, Cooney MK, Allan ID. Long-term epidemiology of infections with Mycoplasma pneumoniae. J Infect Dis 1979; 139:681.
  17. Johnson S. Possibly autoantibody complications in Mycoplasma pneumoniae infection. Clin Infect Dis 2006; 43:1246.
  18. Powell DA, Hu PC, Wilson M, et al. Attachment of Mycoplasma pneumoniae to respiratory epithelium. Infect Immun 1976; 13:959.
  19. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986; 315:161.
  20. Grayston JT, Diwan VK, Cooney M, Wang SP. Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically. Arch Intern Med 1989; 149:169.
  21. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353:1555.
  22. Cornia PB, Hersh AL, Lipsky BA, et al. Does this coughing adolescent or adult patient have pertussis? JAMA 2010; 304:890.
  23. Nennig ME, Shinefield HR, Edwards KM, et al. Prevalence and incidence of adult pertussis in an urban population. JAMA 1996; 275:1672.
  24. Wenzel RP, Fowler AA 3rd. Clinical practice. Acute bronchitis. N Engl J Med 2006; 355:2125.
  25. Dingle JH, Badger GF, Jordan WS Jr. Illness in the home: A study of 25,000 illnesses in a group of Cleveland families, The Press of Western Reserve University, Cleveland 1964. p.68.
  26. Williamson HA Jr. Pulmonary function tests in acute bronchitis: evidence for reversible airway obstruction. J Fam Pract 1987; 25:251.
  27. Müller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007; 7:10.
  28. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157:1453.
  29. Gonzales R, Sande M. What will it take to stop physicians from prescribing antibiotics in acute bronchitis? Lancet 1995; 345:665.
  30. Hoppe JE. Methods for isolation of Bordetella pertussis from patients with whooping cough. Eur J Clin Microbiol Infect Dis 1988; 7:616.
  31. Sotir MJ, Cappozzo DL, Warshauer DM, et al. Evaluation of polymerase chain reaction and culture for diagnosis of pertussis in the control of a county-wide outbreak focused among adolescents and adults. Clin Infect Dis 2007; 44:1216.
  32. Koidl C, Bozic M, Burmeister A, et al. Detection and differentiation of Bordetella spp. by real-time PCR. J Clin Microbiol 2007; 45:347.
  33. Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 361:728.
  34. Centers for Disease Control and Prevention (CDC). Evaluation of rapid influenza diagnostic tests for influenza A (H3N2)v virus and updated case count--United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:619.
  35. Hurt AC, Alexander R, Hibbert J, et al. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol 2007; 39:132.
  36. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003.
  37. Klausner JD, Passaro D, Rosenberg J, et al. Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis. J Infect Dis 1998; 177:161.
  38. Klement E, Talkington DF, Wasserzug O, et al. Identification of risk factors for infection in an outbreak of Mycoplasma pneumoniae respiratory tract disease. Clin Infect Dis 2006; 43:1239.
  39. Uldum SA, Jensen JS, Søndergård-Andersen J, Lind K. Enzyme immunoassay for detection of immunoglobulin M (IgM) and IgG antibodies to Mycoplasma pneumoniae. J Clin Microbiol 1992; 30:1198.
  40. Shuvy M, Rav-Acha M, Izhar U, et al. Massive empyema caused by Mycoplasma pneumoniae in an adult: a case report. BMC Infect Dis 2006; 6:18.
  41. Biberfeld G, Biberfeld P, Wigzell H. Antibodies of surface antigens of lymphocytes and lymphoblastoid cells in cold-agglutinin-positive sera from patients with Mycoplasma pneumoniae infection. Scand J Immunol 1976; 5:87.
  42. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347.
  43. Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007; 44:568.
  44. Tuuminen T, Palomäki P, Paavonen J. The use of serologic tests for the diagnosis of chlamydial infections. J Microbiol Methods 2000; 42:265.
  45. Murdoch DR. Molecular genetic methods in the diagnosis of lower respiratory tract infections. APMIS 2004; 112:713.
  46. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059.
  47. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008; 168:2000.
  48. Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010; 36:601.
  49. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171:1322.
  50. Schuetz P, Müller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9:CD007498.
  51. Prieto B, Alvarez FV. Lack of transferability of results between procalcitonin assays. Clin Chem 2009; 55:2226.
  52. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011; 52 Suppl 4:S346.
  53. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932.
  54. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997; 278:1440.
  55. Jónsson JS, Gíslason T, Gíslason D, Sigurdsson JA. Acute bronchitis and clinical outcome three years later: prospective cohort study. BMJ 1998; 317:1433.
  56. Hallett JS, Jacobs RL. Recurrent acute bronchitis: the association with undiagnosed bronchial asthma. Ann Allergy 1985; 55:568.
  57. Bolser DC. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:238S.
  58. Smucny JJ, Flynn CA, Becker LA, Glazier RH. Are beta2-agonists effective treatment for acute bronchitis or acute cough in patients without underlying pulmonary disease? A systematic review. J Fam Pract 2001; 50:945.
  59. Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:95S.
  60. Becker LA, Hom J, Villasis-Keever M, van der Wouden JC. Beta2-agonists for acute bronchitis. Cochrane Database Syst Rev 2011; :CD001726.
  61. Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev 2012; 8:CD001831.
  62. Jiang L, Li K, Wu T. Chinese medicinal herbs for acute bronchitis. Cochrane Database Syst Rev 2012; 2:CD004560.
  63. Llor C, Moragas A, Bayona C, et al. Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial. BMJ 2013; 347:f5762.
  64. Little P, Rumsby K, Kelly J, et al. Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection: a randomized controlled trial. JAMA 2005; 293:3029.
  65. Smith SM, Fahey T, Smucny J, et al. Antibiotics for acute bronchitis. Cochrane Database Syst Rev 2012; CD000245.
  66. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008; 47:735.
  67. Little P, Stuart B, Moore M, et al. Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial. Lancet Infect Dis 2013; 13:123.
  68. Petersen I, Johnson AM, Islam A, et al. Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database. BMJ 2007; 335:982.
  69. http://publications.nice.org.uk/respiratory-tract-infections-antibiotic-prescribing-cg69/guidance (Accessed on February 20, 2013).
  70. National Quality Forum (NQF). Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis. Available at: http://www.qualityforum.org/MeasureDetails.aspx?actid=0&SubmissionId=1216#p=5&s=n&so=a (Accessed on July 31, 2012).
  71. Barnett ML, Linder JA. Antibiotic prescribing for adults with acute bronchitis in the United States, 1996-2010. JAMA 2014; 311:2020.
  72. Antibiotic/Antimicrobial Resistance: Threat Report 2013. Centers for Disease Control and Prevention Website. Available at: http://www.cdc.gov/drugresistance/threat-report-2013 (Accessed on October 09, 2013).
  73. Gonzales R, Anderer T, McCulloch CE, et al. A cluster randomized trial of decision support strategies for reducing antibiotic use in acute bronchitis. JAMA Intern Med 2013; 173:267.
  74. Linder JA. Antibiotic Prescribing for acute respiratory infections--success that's way off the mark: comment on "A cluster randomized trial of decision support strategies for reducing antibiotic use in acute bronchitis". JAMA Intern Med 2013; 173:273.
  75. Spurling GK, Del Mar CB, Dooley L, et al. Delayed antibiotics for respiratory infections. Cochrane Database Syst Rev 2013; 4:CD004417.
  76. Bergquist SO, Bernander S, Dahnsjö H, Sundelöf B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J 1987; 6:458.
  77. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016.
  78. Bradley JS, Englund JA, File TM, et al. Influenza H1N1: Frontline questions and expert opinion answers. Available at: www.idsociety.org/Content/aspx?id=15743 (Accessed on January 13, 2009).